Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

Among patients who received four-drug consolidation therapy, 84% had measurable residual disease (MRD)-negative status before ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Johnson & Johnson's fixed-dose combination of a PARP inhibitor and anti-androgen therapy, Akeega, could see its label ...

European Commission approves Adcetris, Takeda & Pfizer's antibody-drug combo, for frontline Hodgkin lymphoma. Read more here.

Regarding AI in the dermatology community, ‘there’s fear, but there’s also enthusiasm — sometimes enthusiasm to the point of using things that aren’t ready for prime time,’ says Daneshjou.

Dividend stocks are a smart way to navigate an uncertain market. Besides generating steady passive income, dividend-paying ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...